Group 1 - The Global X China Core Technology ETF (03448) has officially launched on the Hong Kong Stock Exchange, providing investors with a tool to diversify risks in technology stock investments, focusing on seven high-growth technology sectors and 30 leading Chinese technology companies [1] - The ETF tracks the Future Asset China Technology 30 Index, which includes the top 30 companies in China with potential global competitiveness, with an average market capitalization of $65 billion [1] - The top five sectors represented in the ETF are biotechnology (22%), semiconductors (17%), consumer electronics (17%), electric vehicles (15%), and batteries (9%) [1] Group 2 - Over the past few decades, China's manufacturing scale has rapidly expanded, now accounting for 30% of global manufacturing, ranking first in the world [2] - High-tech manufacturing has outpaced traditional manufacturing, indicating China's advancement in the global value chain [2] - In 2024, China's total R&D expenditure reached 3.6 trillion RMB, a year-on-year increase of 8.3%, maintaining its position as the second-largest globally [2] Group 3 - The rise of China's technology industry is expected to continue, with upgrades in high-end manufacturing, increased R&D investment, and deeper globalization [3] - The core technology sectors defined by the ETF are crucial for China's self-reliance in high-end technology and include biotechnology, semiconductors, electric vehicles, batteries, medical technology, robotics, consumer electronics, solar energy, and software [3] - The leading Chinese technology companies are anticipated to significantly increase their domestic market share while becoming global leaders [3]

Core Viewpoint - The Hong Kong Stock Exchange (HKEX) has launched a new policy called "Tech Company Special Line," which provides a confidential listing channel and lowers the threshold for specialized technology and biotechnology companies, attracting more tech firms to consider listing in Hong Kong [1][2]. Group 1: Applicable Entities - The policy is aimed at specialized technology companies (e.g., AI, chips, new energy) and biotechnology companies (e.g., innovative drugs, medical devices), particularly those in early stages or with non-commercialized products [3][4]. - Core thresholds include being classified under HKEX's definitions of "specialized technology" (Chapter 18C) or "biotechnology" (Chapter 18A) [4][5]. Group 2: Self-Assessment and Application Process - Companies must assess their eligibility by checking if they meet the criteria outlined in the self-assessment form available on the HKEX website [8]. - If uncertain, companies can fill out the inquiry form and send it to HKEX for preliminary feedback within one week [9]. Group 3: Confidential Submission Process - The first step involves signing a Non-Disclosure Agreement (NDA) with HKEX to ensure that submitted materials are only visible to the review team [11]. - Companies must submit a "confidential version" of their materials, including a checklist of required documents [12][13]. - The review team will provide feedback within 30 days, focusing on technical feasibility and compliance [14]. Group 4: Exclusive Services of "Tech Company Special Line" - Companies can receive one-on-one guidance from HKEX experts, including interpretations of listing rules and fundraising strategies [16]. - Eligible companies can benefit from a fast-track review process, reducing the review period to 30 days [17]. - Flexible equity design is allowed, enabling founders to retain control without additional proof of "innovation" [18]. Group 5: Common Pitfalls to Avoid - Companies should provide clear descriptions of their technology and avoid vague claims without supporting evidence [21]. - Transparency in related-party transactions is crucial to avoid compliance issues [22]. - Establishing a diverse investor base is important to strengthen investor relations [24]. Group 6: Post-Listing Compliance - Continuous information disclosure is required, including updates on technological commercialization and significant collaborations [27]. - Companies are encouraged to maintain market value by releasing quarterly research updates and engaging with analysts [28]. - A green channel for refinancing allows specialized companies to issue new shares through a simplified process [29]. Group 7: Comparison with Other Markets - The HKEX's "Tech Company Special Line" offers no profitability requirement, a shorter review period, and lower information disclosure pressure compared to A-shares and U.S. markets [30][31].

Group 1 - The US dollar index increased by 0.56%, currently at 99.439 points before the Federal Reserve's interest rate decision [1] - The yield on the 10-year US Treasury bond narrowed to less than 2.8 basis points, reported at 4.3481%, while the 2-year Treasury yield rose by 1.6 basis points, falling below 3.89% [1] Group 2 - Spot gold decreased by 0.76%, currently at $3301 [2] - The S&P 500 index rose by 0.23%, the Dow Jones remained roughly flat, the Nasdaq increased by 0.43%, the biotechnology index rose by 1%, the Philadelphia semiconductor index increased by 1.2%, the banking index rose by 0.5%, and the Russell 2000 index increased by 0.9% [2]

Group 1 - Major industry ETFs showed mixed performance, with the biotechnology and semiconductor ETFs both rising by 0.7% [1] - The biotechnology index ETF is currently priced at 134.78, reflecting an increase of 0.93 (+0.69%) with a total market value of 10.702 billion and a year-to-date change of +2.04% [2] - The semiconductor ETF is priced at 294.90, up by 2.00 (+0.68%), with a total market value of 34.86 billion and a year-to-date increase of +21.77% [2] Group 2 - The global airline ETF decreased by 0.8%, currently priced at 24.05, down by 0.20 (-0.82%), with a total market value of 0.0757575 billion and a year-to-date decline of -5.13% [1][2] - The utility ETF increased by 0.51%, priced at 85.01, with a total market value of 12.341 billion and a year-to-date change of +13.90% [2] - The financial sector ETF rose by 0.23%, priced at 52.92, with a total market value of 589.02 billion and a year-to-date increase of +10.27% [2]

Group 1 - The China Securities Regulatory Commission (CSRC) has optimized the registration review process for Hong Kong mutual recognition funds to enhance investor protection and ensure stable operations of these funds, requiring a minimum asset scale of 200 million RMB in the year prior to application [1] - Several small and medium-sized public fund companies have begun shutting down their mobile applications due to low user engagement and high operational costs, with companies like Ping An Fund and Guotai Junan Fund announcing similar plans [1] Group 2 - The Ministry of Finance has allocated a budget of approximately 90 billion RMB for childcare subsidies this year, with the central government covering about 90% of the funding needed for local governments [2] - In the first half of the year, 10 healthcare companies have listed in Hong Kong, raising a total of 2.1 billion USD, while 35 more companies have submitted listing applications [2] - A report indicates that by 2024, the revenue share of self-developed Chinese games from overseas sales is expected to reach 33.62%, with the Chinese and US gaming markets projected to be worth 47 billion USD and 46.1 billion USD respectively [2] Group 3 - Giant Star Legend has announced a partnership with Yushu Technology to develop consumer-grade robots, with plans to allocate approximately 38.2% of their recent fundraising for expanding retail channels, including vending machines and smart devices [3] - Huawei has launched its new flagship tablet, the MatePad Pro, featuring HarmonyOS 5 and starting at a price of 3,999 RMB [3] Group 4 - Greenland Holdings has refuted rumors regarding its CEO's disappearance, confirming that he is on personal leave but remains in his position [4] - Glencore plans to cut costs by 1 billion USD and has raised its long-term profit forecast for its commodities trading division for the first time since 2017, with expected profits now between 2.3 billion and 3.5 billion USD [4] - Zhongwang Software is facing a copyright infringement lawsuit from Autodesk in the US, which the company intends to contest vigorously [4] Group 5 - Pudong Construction reported a 1.89% decrease in the number of new engineering projects signed in Q2, with a 22.53% drop in project value to 3.278 billion RMB [5] - Anhui Construction announced a slight increase of 0.65% in new contract value for its engineering business, totaling 33.523 billion RMB [5] - Sinopec Oilfield Services has won a contract worth 3.597 billion RMB for a natural gas pipeline project, accounting for 4.44% of its projected revenue for 2024 [5] - Inner Mongolia Huadian reported a decline in revenue by 8.75% to 9.827 billion RMB and a net profit drop of 11.91% to 1.557 billion RMB for the first half of the year [5] Group 6 - Weihong Co. reported a 9.51% increase in revenue to 260 million RMB for the first half of the year, but a 28.86% decrease in net profit to approximately 29.25 million RMB [6] Group 7 - The Shanghai Composite Index rose by 0.17% despite a mixed performance in the market, with significant declines in high-profile stocks, while sectors like film, oil and gas, and baby products saw gains [7]

（编辑 袁冠琳） 证券日报网讯 四川双马7月30日在互动平台回答投资者提问时表示，未来公司将持续推动核心业务的深 入发展，聚焦于空间大、成长性好、盈利能力良好的生物科技等领域，延伸寻找有协同效应的业务，确 保长期的可持续发展和增长，为股东创造持续的股东回报。若涉及相关情况，公司将根据相关法律法规 及时履行信息披露义务。 ...

据了解，中华香港生物科技指数选股范畴包括：在香港上市的生物科技公司。 中华香港生物科技指数于2018年11月14日推出，指数基值2000点，成份股数目变动的只。 7月30日消息，截至当日收盘，中华香港生物科技指数报9498.3788点，下跌238.98点，跌幅2.45%。今 日最高9872.6885点，今日最低9282.4521点。 本文源自：金融界 作者：行情君 ...

上半年10家医疗健康公司在港上市 35家递交上市申请 智通财经7月30日电，最新数据显示，今年上半年已有10家医疗健康公司在港上市，融资总额达21亿美 元。截至本周，还有35家医疗健康行业公司已递交上市申请，其中包括16家根据第18A章递交申请的生 物科技公司。今年5月，港交易所推出"科企专线"，进一步便利了生物科技公司及特专科技公司申请上 市，并允许这些公司可以选择以保密形式提交上市申请。香港恒生生物科技指数年初至今涨幅已达 97%。（智通财经记者 赵昕睿） ...

Core Viewpoint - The Hong Kong Innovation and Technology Bureau aims to increase the number of smart production lines supported under the "New Industrialization Subsidy Scheme" to at least 130 by 2027, with current progress aligning with expectations [1][2] Group 1: Subsidy Program Details - Since the launch of the "Subsidy Scheme," the New Industrial Review Committee has supported 66 applications, involving over 100 production lines across various industries including food manufacturing, textiles, construction materials, medical devices, biotechnology, and renewable energy [1] - Approximately 40% of the projects under the "Subsidy Scheme" have requested funding amounts below HKD 2.8 million, indicating a significant number of applicants may benefit from the new optimization measures aimed at expediting the approval process [2] Group 2: Optimization Measures - The latest optimization measures intend to accelerate the approval process for projects with funding requests below HKD 2.8 million, simplifying documentation requirements and review procedures [1][2] - The average notification time for applicants regarding approval results is currently 35 working days, with expectations for further reductions following the implementation of the new measures [2] Group 3: Future Initiatives - The Hong Kong Innovation and Technology Bureau plans to launch a two-year "Manufacturing and Production Line Upgrade Support Pilot Scheme" within the year to provide matching grants for local manufacturers to adopt smart production technologies [2] - A consultancy study will be initiated to explore the long-term development of new industries in Hong Kong, focusing on leveraging innovative technologies to assist traditional manufacturing in upgrading and transforming [2]

Group 1 - The core viewpoint of the news highlights the performance of various healthcare indices, with the CSI Hong Kong Stock Connect Healthcare Index rising by 2%, the CSI 300 Healthcare Index increasing by 1.7%, and the Hang Seng Hong Kong Stock Connect Innovative Drug Index up by 1.5% [1][4][11] - The CSI Hong Kong Stock Connect Healthcare Index focuses on leading companies in the Hong Kong healthcare sector, comprising 50 stocks from medical devices, biopharmaceuticals, chemical drugs, and other healthcare-related industries [3] - The CSI Innovative Drug Industry Index targets leading A-share innovative drug companies, consisting of no more than 50 stocks involved in innovative drug research and development [6] - The CSI Biotechnology Theme Index centers on leading A-share biotechnology companies, including no more than 50 stocks related to gene diagnostics, biopharmaceuticals, blood products, and other human biotechnology [8] - The CSI 300 Healthcare Index encompasses leading A-share healthcare companies, covering segments such as chemical pharmaceuticals, medical services, and medical devices [10]